Psychological Morbidity and Facial Volume in HIV Lipodystrophy: Quantification of Treatment Outcome

NHS Lothian50 enrolled

Overview

The hypotheses of this study were that: 1. HIV lipodystrophy is associated with psychological morbidity relating to body image, anxiety and depression. 2. Treatment of HIV lipodystrophy using autologous fat transfer, polylactic acid or Bio-alcamid, is associated with an improvement in psychological morbidity and anatomical volume of treated areas. 3. The DI3D system is a valid and reproducible method of recording and measuring facial 3-D volume.

as above

Study Type

OBSERVATIONAL

Enrollment

Conditions

HIV-Associated Lipodystrophy Syndrome

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * HIV facial lipoatrophy * concurrent antiretrovirals Exclusion Criteria: * known psychological disorder * skin allergies * significant medical problems precluding anaesthesia

Outcomes

Primary Outcomes

measurement of 3-D facial volume

3-D facial camera

Time frame: 2 years

Secondary Outcomes

psychological outcome

derriford appearance scale hospital anxiety and depression scale

Time frame: 2 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.